Hashizume S
Gan To Kagaku Ryoho. 1985 Feb;12(2):284-8.
The antitumor effects of recombinant human leukocyte interferon (rIFN-alpha A) on human malignant melanomas (SK-14 and AM-1) were studied using a nude mouse-human tumor xenograft system. Intratumoral administration of 6 X 10(5)U of rIFN-alpha A significantly inhibited proliferation of SK-14 and inhibited that of AM-1 moderately. This result indicated that the sensitivity of human melanoma to rIFN-alpha A varied with the cell line. The effects of rIFN-alpha A were found to be dose-dependent, in that it was necessary for a relatively large dose of rIFN-alpha A to be injected in order to produce an appreciable effect on human tumors. Antitumor activities achieved depended on the routes of administration used, intratumoral being more effective than intraperitoneal. The effects of rIFN-alpha A were about equal to those of human lymphoblastoid interferon (HLBI).
利用裸鼠-人肿瘤异种移植系统研究了重组人白细胞干扰素（rIFN-αA）对人恶性黑色素瘤（SK-14和AM-1）的抗肿瘤作用。瘤内注射6×10⁵U的rIFN-αA可显著抑制SK-14的增殖，并中度抑制AM-1的增殖。该结果表明人黑色素瘤对rIFN-αA的敏感性因细胞系而异。发现rIFN-αA的作用具有剂量依赖性，即为了对人肿瘤产生明显作用，需要注射相对大剂量的rIFN-αA。所实现的抗肿瘤活性取决于所用的给药途径，瘤内给药比腹腔内给药更有效。rIFN-αA的作用与人淋巴母细胞干扰素（HLBI）的作用大致相当。
